As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company. We believe ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target of $23.00. Yi Chen has given his Buy rating due to a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company. A bid from Blackstone and TPG could reportedly value the company ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

Bausch & Lomb (NYSE:BLCO) jumped 7.5% on a report that private equity firms TPG (TPG) and Blackstone (BX) are working on a joint bid for the eyecare company. Several other PE shops that have been ...

It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.

Bausch Health turned down recent debt-restructuring proposals from bondholders as it explores a sale of its Bausch + Lomb vision care subsidiary that could bring in billions of dollars to pay ...

Private equity players TPG and Blackstone are planning a joint bid for Canadian contact lens supplier Bausch + Lomb, Financial Times reported on October 14 citing people familiar with the matter.

Net income attributable to Bausch + Lomb Corporation for the third quarter of 2024 was $4 million, as compared to a net loss of $84 million for the third quarter of 2023, a favorable change of $88 ...